

TABLE 2 Kaplan-Meier plotter to determine the effect of different clinicopathological factors on the expression of PSMD13 gene and clinical prognosis in LIHC

Clinicopathological characteristics	Overall survival (n = 364)			Progression-free survival (n = 370)		
	N	Hazard ratio	P-value	N	Hazard ratio	P-value
Gender						
Female	118	1.84 (1.06-3.2)	0.029	120	0.78(0.46-1.3)	0.34
Male	246	1.58 (1.01-2.48)	0.044	246	1.57(1.03-2.4)	0.033
Stage						
1	170	1.47 (0.8-2.71)	0.21	170	1.48(0.85-2.56)	0.16
2	83	3.08 (1.24-7.69)	0.011	84	1.55(0.76-3.14)	0.22
3	83	2.38 (1.3-4.36)	0.004	83	2.01(1.16-3.48)	0.011
3+4	87	2.36 (1.31-4.24)	0.0032	88	1.83(1.07-3.13)	0.025
Grade						
1	55	0.67 (0.26-1.7)	0.4	55	2.85(1.23-6.58)	0.01
2	174	1.96 (1.16-3.3)	0.01	175	1.83(1.1-3.05)	0.018
3	118	1.59 (0.87-2.92)	0.13	119	0.53(0.32-0.89)	0.015
AJCC-T						
1	180	1.48 (0.83-2.65)	0.18	180	1.43(0.84-2.44)	0.19
2	90	2.29 (1.05-5.01)	0.033	92	1.53(0.82-2.88)	0.18
3	78	2.3 (1.25-4.26)	0.0063	80	1.95(1.1-3.46)	0.02
Vascular invasion						
none	203	1.35 (0.81-2.26)	0.25	204	0.76(0.48-1.22)	0.26
micro	90	1.67 (0.77-3.6)	0.19	91	1.46(0.82-2.59)	0.19
Hepatitis virus						
yes	150	1.76 (0.8-3.84)	0.15	152	0.8(0.5-1.28)	0.35
none	167	2.27 (1.43-3.59)	0.00035	167	1.68(1.08-2.6)	0.019
Alcohol consumption						
yes	115	2.08 (1.11-3.89)	0.02	115	1.37(0.78-2.41)	0.27
none	202	1.79 (1.12-2.85)	0.014	204	1.4(0.94-2.09)	0.1
Sorafenib treatment						
treated	29	7.59(1.93-29.84)	0.001	30	0.53(0.23-1.21)	0.13